eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention.
.chemotherapy involved two hours at the hospital every other week. he'd leave wearing a fanny pack that would continue to deliver treatment for 48 straight hours, one slow drip at a time.
.